Cat. No.: DIA-0230103
Product Information | |
---|---|
CAS No. | 1352608-82-2 |
Formula | C22H18FN7 |
Molecular Weight | 399.42 |
SMILES | CC1=NC(=CC=C1)C2=C(N=C(CNC3=CC=CC=C3F)[NH]2)C4=C[N]5N=CN=C5C=C4 |
Target | TGF-β receptor ALK4/ALK5 |
Product Description | Vactosertib (TEW-7197) is a highly potent, selective, and orally bioavailable TGF-β receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively. Phase 1. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.